Ibritumomab tiuxetan (Zevalin) for non-Hodgkin's lymphoma.
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005252:Fees, Pharmaceutical; D006207:Half-Life; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D016499:Radioimmunotherapy / Q000009:adverse effects / Q000191:economics; D016032:Randomized Controlled Trials as Topic; D013610:Tachycardia / Q000139:chemically induced; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan